InvestorsHub Logo
Followers 38
Posts 5017
Boards Moderated 2
Alias Born 08/05/2002

Re: errata post# 4356

Tuesday, 06/30/2015 3:33:05 PM

Tuesday, June 30, 2015 3:33:05 PM

Post# of 9141
Yes,

That is true. They must be somewhat satisfied or one would assume they would make a move. Of course to land a real industry veteran would surely cost some money ..... but that knowledge is worth it IMO if they intend to move forward themselves.

I didn't go to Detroit for the annual meeting cause I was too busy but if I had .... that is the only thing I would have gone for. To look Maggiore and Yaldoo in the eye and ask what they are thinking. No question in my mind both are sharp individuals. No question in my mind that John Payne very likely could get ZIVO in front of just about any animal pharma. And of course they know far more than they could say ..... but to hear what they are thinking and assess words used and body language adds much more flavor.

I have said it before, if the bioactive is novel and a new discovery that proves out to have auto immune and anti inflammatory properties, not to mention be able to regulate cholesterol levels, there is quite a bit of value. The question is how much money and how long ..... and can Dahl get it over the finish line before diluting the company to death ??

Wellmetris IMO does have value as well. Need to sell/JV it with an industry player. I am seeing Dahl reserving a piece for mgmt which I don't agree with at all ..... and his continued assertion of a raise for Wellmetris doesn't put ZIVO holders at disadvantage is pure BS. Dahl has had almost 2 full years to raise the money to get Wellmetris off the ground. Hasn't done it.

Soooooo what are Maggiore and Yaldoo seeing in Dahl ... and Rice for that matter .... to keep them in the chair ??

Amigo Mike
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ZIVO News